Sign in
Taking peoplePhase 3

Systematic Adjunction of Vasopressine in Septic Shock

Key facts

Who runs it
Assistance Publique Hopitaux De Marseille
Where
France3 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
120 people, planned
Started
24 Mar 2026
Expected to end
Feb 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Vasopressin administration
  • Sodium chloride administration
Record updated
26 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patient aged 18 or over
  • Patient who has consented to take part in the research or patient whose close relative has consented to take part in the research or, failing that, patient being included in an emergency situation
  • Patient in septic shock with adapted cardiac output
  • Patient in whom noradrenaline dosage has been greater than 0.3μg/kg/min for less than 12 hours
  • Patients benefiting from or affiliated to social security

Who cannot take part

  • Patient with acute coronary syndrome
  • Patient with known history of acute coronary syndrome
  • Known allergy to vasopressin or its excipients
  • Patient with suspected mesenteric ischemia
  • Patient with hyponatremia < 130mmol/L,
  • Minors
  • Pregnant women
  • Patients under legal guardianship or curatorship
  • Patients under judicial protection

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Septic shock is a syndrome associated with severe infection and a mortality rate of approximately 45%. In line with current recommendations, norepinephrine is the first-line vasopressor used in patients with septic shock. In a previous study, norepinephrine doses above 1 µg/kg/min were associated with mortality rates over 90%. In the same study, doses above 0.3 µg/kg/min were associated with a mortality rate of 40%. An increased mortality compared to the general 40% mortality of septic shock appears to be associated with norepinephrine doses as low as 0.3 µg/kg/min.

Read full original descriptionShow less

Vasopressin stimulates V1 receptors, primarily located on vascular smooth muscle cells. When V1a receptors are stimulated, they induce vasoconstriction by activating protein kinase C via a Gq protein and various second messengers.

Its use is validated in refractory shock states by international guidelines as a second-line vasopressor. This indication was further reinforced in the 2021 update of the septic shock management recommendations.

The VASST study, a randomized controlled trial, assessed the effects of vasopressin versus norepinephrine in septic shock. It found no overall difference in mortality between the two groups. However, in less severe cases where norepinephrine doses were below 14 µg/min before randomization, vasopressin was associated with significantly lower mortality, suggesting potential benefits from early introduction of a second vasopressor.

The VANISH trial failed to confirm this hypothesis, possibly due to broad inclusion criteria and unclear protocol regarding the combined use of both agents. Our hypothesis is that (1) vasopressin is beneficial when used synergistically with norepinephrine; (2) due to its negative effect on cardiac output (as shown in previous studies), vasopressin should only be administered to patients in the hyperdynamic phase of septic shock.

The hypothesis is that the systematic addition of vasopressin to norepinephrine therapy in a hyperdynamic septic shock subpopulation would improve patient outcomes.

The 2 groups in the trial

  • VassopressineTreatment being tested

    Treatment: Vasopressin administration

  • PlaceboPlacebo, for comparison

    Treatment: Sodium chloride administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Systematic Adjunction of Vasopressine in Hyperkinetic Septic Shock Patients - A Multicentric RCT
Record updated
26 October 2026